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Abstract: Patients with non-transfusion-dependent thalassemia (NTDT) experience many clinical
complications despite their independence from frequent transfusions. Morbidities in NTDT stem
from the interaction of multiple pathophysiological factors: ineffective erythropoiesis, iron overload
(IOL), and hypercoagulability. Ineffective erythropoiesis and hemolysis are associated with chronic
hypoxia and a hypercoagulable state. The latter are linked to a high prevalence of thromboembolic
and cerebrovascular events, as well as leg ulcers and pulmonary hypertension. IOL in NTDT patients
is a cumulative process that can lead to several iron-related morbidities in the liver (liver fibrosis),
kidneys, endocrine glands (endocrinopathies), and vascular system (vascular disease). This review
sheds light on the pathophysiology underlying morbidities associated with NTDT and summarizes
the mainstays of treatment and some of the possible future therapeutic interventions.
Keywords: non-transfusion dependent thalassemia; morbidity; management; ineffective erythropoiesis;
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1. Introduction
The group of disorders referred to as the thalassemias is one of the most common monogenic
diseases worldwide. Having been historically clustered in the Mediterranean, North Africa, and
South Asia, thalassemias are now encountered in other regions around the globe with the more recent
immigration movements towards areas of lower prevalence [1,2]. Thalassemias result from an inherited
imbalance between α and β chains of hemoglobin, instigating ineffective erythropoiesis [3].
Non-transfusion dependent thalassemia (NTDT) is a group of thalassemic disorders including
patients who do not require frequent blood transfusions for survival. Those patients have Hemoglobin
H disease or reduced expressivity of the β genes (homozygous β+ or compound heterozygous β+/β0
in addition to other variants where the end result remains α/β imbalance (Table 1) [4]. Patients
with NTDT may still require occasional or more frequent red blood cell (RBC) transfusion therapy in
certain circumstances including but not limited to significant infection, pregnancy, periods of rapid
growth, or surgery [2,5]. Over the years, many individual studies have showed a clear variation in the
complications seen between transfusion dependent (TDT) and non-transfusion dependent (NTDT)
thalassemic patients. The difference in management (i.e., limited transfusion, limited chelation, more
frequent splenectomies) is an attributable factor in such discrepancy in the multimorbidity profiles of
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TDT and NTDT [6–8]. Ultimately, the OPTIMAL CARE study was one of the first landmark studies that
confirmed the high prevalence of unique morbidities in patients with β-thalassemia intermedia (TI)
as compared to β-thalassemia major (TM) [9]. The need to consider the NTDT patients as a separate
population, in terms of guidelines for complications screening and management, has since been
acknowledged. This review describes the underlying pathophysiology that separates NTDT from TDT,
and delineates the various morbidities associated with this subgroup of thalassemia while comparing
it to TDT. Discussion of current and prospective options for management follows.
Table 1. Several β-Thalassemia variants that can present as non-transfusion dependent thalassemia.
Homozygosity for mild forms of β+ thalassemia
Compound heterozygosity for β+/β0 thalassemia
Compound heterozygosity for β-thalassemia and another β chain variant (e.g., β-thal/hemoglobin HbE)
Coinheritance of homozygous β-thalassemia and hereditary persistence of fetal Hemoglobin [HPFH])
Coinheritance of homozygous β+ thalassemia with α-thalassemia (e.g., β+/β+ with −α/−α, −−/αα, −α/αα, or −−/−α)
Coinheritance of heterozygous β-thalassemia and triplicated or quadruplicated α genes (eg, αα/ααα or αα/ααα)
Dominant forms of β-thalassemia
β0 thalassemia: no production of β chains; β+ thalassemia: reduced production of β chains (may be mild, moderate
or severely reduced).
2. Pathophysiology
Both TDT and NTDT share the pathological cascade of α-to-β globin chain imbalance, ineffective
erythropoiesis, and an array of subsequent pathophysiological mechanisms underlying the morbidity
profiles [10]. While transfusion therapy helps suppress ineffective erythropoiesis, it is also associated
with secondary complications [11]. Since current therapeutic strategies for NTDT are primarily initiated
when symptoms or complications occur, the clinical picture of NTDT patients, as compared to TDT
patients, is predominated by the long-term effects of chronic anemia and tissue hypoxia and their
compensatory reactions, including bone marrow expansion, ineffective erythropoiesis, and increased
intestinal iron absorption [12,13].
2.1. Ineffective Erythropoiesis
α- and β-globin chain imbalance leads to a chronic state of anemia and ineffective
erythropoiesis [5]. In β-thalassemias, for example, the formation of hemichromes from excess α-globin
chains stimulates an oxidative stress that is able to damage membranes of both mature and immature
erythroid cells [14]. The increase in erythropoietin driven by anemia and the consequent cascade of
Janus Kinase 2 (JAK2)-dependent phosphorylation events ultimately expand the erythroid lineage
within the bone marrow. This expansion, however, fails to produce enough mature RBCs in the
peripheral blood, and rather results in characteristic bone deformities and formation of hematopoietic
pseudotumors and/or hepatosplenomegaly [15].
2.2. Chronic Hemolytic Anemia
Both intravascular and extravascular hemolysis can occur. Lower hemoglobin levels in patients
with NTDT are associated with higher prevalence of complications [16]. It is thought that the exposure
to senescence antigens during ineffective erythropoiesis, chronic platelet activation, and increased
platelet aggregation lead to a hypercoagulable state in NTDT [17]. Chronic hemolytic anemia is
associated with chronic hypoxia, generation of reactive oxygen species, and dysregulation of the
hepcidin/iron homeostasis in favor of increased iron absorption. Both anemia and iron overload can
further worsen ineffective erythropoiesis and complicate the pathophysiological picture [18].
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2.3. Iron Overload
No active mechanism for excess iron excretion exists in the human body. The mechanism of iron
overload in TDT and NTDT is distinct in many aspects. Complications associated with iron overload
appear much earlier in patients with TDT as compared to patients with NTDT [19]. Ineffective
erythropoiesis plays a central role in the process in patients with NTDT and results in significant
iron overload despite absent or minimal transfusional iron burden. Ineffective erythropoiesis triggers
suppression of hepcidin synthesis leading to the upregulation of intestinal iron absorption, and iron
release from macrophages [20]. Twisted gastrulation factor-1, hypoxia inducible transcription factors,
transmembrane protease serine-6 (TMPRSS-6), erythroferrone, and possibly growth differentiation
factor-15 have been suggested to play a role in hepcidin regulation [21–24]. Although the exact
mechanisms are still incompletely understood, the common end point is an increased iron availability
and release in the circulation with subsequent end-organ damage to the liver, endocrine glands,
myocardium, and others.
3. Morbidities in NTDT
Figure 1 depicts the interplay between NTDT morbidities and pathophysiology.
3.1. Thrombosis
The hypercoagulable state in NTDT is associated with a high frequency of thromboembolic
complications, such as deep vein thrombosis, portal vein thrombosis, pulmonary thromboembolism,
cerebral thrombosis, and recurrent arterial thrombosis. Thromboembolic events are more highly
prevalent in patients with NTDT as compared to patients with well-transfused TDT; splenectomized
patients with NTDT were at a significantly higher risk for thromboembolic events [25,26]. Independent
risk factors are splenectomy, serum ferritin level ≥ 1000 ng/mL, hemoglobin level < 9 g/dL, and age >
35 years [9,26,27]. In splenectomized NTDT patients, nucleated RBC count > 300 × 106/L, platelet >
500 × 109/L, and RBC transfusion naivety were associated with higher prevalence of thromboembolic
disease [27].
Ischemic strokes have been reported in combination with thromboembolic disease and linked to
cardiac valvular lesions (elastic tissue defects) or atrial fibrillation [28]. Arterial stenosis on magnetic
resonance angiography was found in 27.6% of 29 asymptomatic splenectomized NTDT adults, most
commonly occurring in the internal carotid artery [29].
Simultaneously, silent thrombosis can occur, as subclinical thrombi in microvasculature of lungs
and brain have been described on autopsy in the absence of other known risk factors [30]. Silent
cerebral infarcts rate in TI patients was estimated at 27–60%, and white matter lesions frequency
correlated with age, transfusion naivety, and splenectomy [31]. Higher liver iron concentration (LIC)
values correlated with abnormal findings on positron emission tomography-computer tomography
studies [32]. The clinical significance of these findings and the role of iron overload as an independent
risk factor are to be clarified.
Int. J. Mol. Sci. 2018, 19, 182 4 of 16Int. J. Mol. Sci. 2018, 19, x FOR PEER REVIEW  4 of 16 
Int. J. Mol. Sci. 2018, 19, 182; doi:10.3390/ijms19010182 www.mdpi.com/journal/ijms 
 
Figure 1. (a) Pathophysiology related to NTDT, and (b) qualitative representation of interplay between NTDT morbidities and pathophysiology. Some independent risk 
factors that were studied were also added. 
Figure 1. (a) Pathophysiolog rel t t , ( ) lit ti e representation of interplay between NTDT morbidities and pathophysiology. Some indepe dent
risk factors hat were studied were lso added.
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3.2. Cardiac Disease
Cardiac disease is the major cause of death in both TDT and NTDT populations [33–35]. While
the main finding in TDT was iron overload leading to left ventricular (LV) dysfunction, cardiac failure,
and cardiogenic death, most cardiac disease in NTDT relates to chronic right heart failure, secondary
to pulmonary hypertension (PHT) [12,35]. Iron deposition in the heart is more prevalent and happens
at a faster rate in TDT patients as compared to NTDT patients [19,36,37]. Older NTDT patients may
still be prone to LV decompensation [13,34]. Several multicentric cross-sectional studies showed
a higher prevalence of rhythm disorders, pericardial disease, and valvular abnormalities in NTDT
as compared to healthy controls. However, high cardiac output (CO), increased pulmonary vascular
resistance (PVR), and PHT were the most significant cardiac findings, especially when compared to
TDT [12,33,35]. Increased CO stems from chronic anemia/hypoxia and related shunt development
due to increased intramedullary and extramedullary erythropoiesis. HbF’s increased oxygen affinity
and the dilatation of blood vessels secondary to coexistent elastic tissue injury, may also contribute
to the increased CO [13,38]. Increased PVR has a multifactorial origin: besides endothelial injury
from high CO, NTDT patients suffer from recurrent respiratory tract infections, chest wall deformities,
extramedullary hematopoietic masses (that may be intrapulmonary), and age-related diffuse elastic
disorders [38]. Iron overload may play an added role, given the known impact of hemosiderosis on
pulmonary fibrosis. However, with universally lower ferritin level in NTDT and appropriate iron
chelation therapy practices when needed, this remains a minor factor [39].
3.3. Pulmonary Hypertension
PHT is a complication of disease progression in the absence of transfusion therapy [12].
Anecdotally, a study reported PHT in 66% of TDT patients who had inadequate transfusion
management, reinforcing the impact of long-term hypoxia [40]. Hypercoagulability, in the form
of chronic thromboembolic disease, has also been implicated in the pathophysiology, as autopsies
revealed extensive pulmonary arterial lesions in thalassemic patients who underwent splenectomy [28].
The prevalence of PHT was found to be 21.5% with groups of age 17.05 ± 5.8 years, but can reach
64% with older groups [34,41]. NTDT patients (4.8%) are 5 times more likely to have PHT than
TDT (1.1%) patients. Risk factors were determined to be splenectomy, naivety to iron chelation
therapy, naivety to hydroxyurea treatment, naivety to RBC transfusion therapy, a nucleated RBC
count greater than 300 × 106/L, a history of previous thromboembolic events, and older age [42,43].
The negative effect of hemolysis on nitric oxide and arginine availability has been heavily implicated
in this phenomenon [44]. Annual routine echocardiography assessing tricuspid valve jet velocity is
recommended, with a threshold of 3.2 m/s indicating a positive predictive value of 93.3% [42,43].
Current guidelines for PHT management with a cardiologist are used in NTDT, as more studies are
needed for this specific population [11].
3.4. Leg Ulcers
NTDT patients have a higher risk of developing leg ulcers compared to the regularly transfused
TDT patients [45]. Increased incidence in NTDT patients has been noticed especially in poorly
controlled disease. Their typical location is at the medial and lateral malleoli, and they are mostly
seen during the second decade of life, with increasing risk with age [46,47]. Being recurrent and
slow to heal, leg ulcers are associated with significant morbidity by causing pain and disability [48].
Pathogenesis of leg ulcers is the result of interplay of many factors, notably chronic anemia and
hypercoagulability. In addition, elevated venous pressure due to liver injury or right heart failure
and RBC membrane defects and rigidity contribute to poor tissue oxygenation and render the skin
injury-prone to minimal trauma [46,49]. No clear-cut recommendations exist for management of leg
ulcers. Although previously theorized that the oxygen-retaining capacity of HbF further contributes
to incidence of leg ulcers, increased HbF levels was found to be protective from leg ulcers [5,9,50].
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Additionally, iron chelation and blood transfusions are beneficial with no clearly defined guidelines.
Topical antibiotics, occlusive dressing, and leg elevation are helpful conservative measures [5,49].
3.5. Hepatobiliary Complications
As the majority of iron accumulation targets the liver in NTDT, patients are at increased risk
of developing liver fibrosis, cirrhosis, and eventually hepatocellular carcinoma (HCC), mainly in
non-chelated patients [51]. HCC prevalence is higher in NTDT as compared to TDT patients [52].
Incidence of HCC in thalassemia patients has been increasing with time. Iron overload is the single
most important risk factor in patients who do not have chronic hepatitis C (HCV). Iron overload is
associated with the formation of toxic free radicals and damages tumor suppressor genes and DNA
repair genes. Additionally, iron overload accelerates the process of liver cirrhosis via its profibrogenic
effects. It is important to recognize that iron overload may be associated with HCC even in the absence
of liver cirrhosis [52,53]. HCV infection is a second key factor and appears to work in synergy with iron
overload to increase risk of HCC development. On the other hand, hepatitis B virus (HBV) infection,
despite its correlation with half HCC cases worldwide, has no established role in hepatic carcinogenesis
in thalassemia patients [51].
Screening is necessary for early detection and treatment given the absence of symptoms in
82% of patients with NTDT affected by HCC. Close Surveillance of iron overload via non-invasive
quantification of LIC with R2 or R2* MRI is favored over the older invasive liver biopsy [54]. However,
the widely available and inexpensive method of serum ferritin measurement remains the most
heavily used method, especially in resource-poor areas where MRI is unavailable, despite frequent
underestimation of the actual iron burden in NTDT patients [55,56]. Additionally, NTDT patients
with HCV infection, HBV infection, serum ferritin ≥ 1000 ng/mL, LIC ≥ 5 mg Fe/g dry weight (dw),
or advanced cirrhosis, are recommended to undergo biannual hepatic ultrasound assessment for
HCC screening.
Chronic hemolytic anemia in NTDT leads to formation of gallstones. Symptomatic gallstones
should be treated with cholecystectomy. In addition, in the absence of symptoms of cholelithiasis,
the gallbladder should be inspected during splenectomy and intervention should be considered as
splenectomized patients are at a high risk should cholecystitis develop [57].
3.6. Extramedullary Hematopoiesis
Reactivation of dormant hematopoietic sites from fetal life is common during states of chronic
ineffective erythropoiesis [58]. These findings parallel the fact that extramedullary hematopoietic
masses (EHM) occur almost exclusively in NTDT patients compared to TDT (20% vs. <1%). EHMs in
TDT occur when transfusion is inadequate, a quasi-NTDT state [8,9]. Physiologically speaking, the use
of regular blood transfusions can decrease the need for extramedullary hematopoiesis; thus resulting
in relative inactivity of these tissues, and leading to the shrinkage of any possible mass. Expansion of
hematopoietic tissue in response to ineffective erythropoiesis can involve the reticuloendothelial
system, resulting in pseudotumors in the liver, spleen, and other sites [58]. Risk factors for
extramedullary hematopoietic tumors include male sex, older age, and lower HbF levels [10,19,50].
In clinical practice, more attention is allocated to paraspinal extramedullary hematopoieses, which
account for 11–15% of EHMs and put patients at risk of spinal cord compression [59]. Management
for symptomatic spinal masses can range from transfusion and hydroxyurea therapy to radiation and
surgical decompression [5,11,58].
3.7. Bone Disease
Bone abnormalities, including facial bone deformities, protrusion of the upper jaw, obliteration
of maxillary sinuses, and osteoporosis, appear to be more marked in NTDT as compared to TDT
as a result of the enhanced ineffective erythropoiesis and consequent bone marrow expansion [60].
Patients with NTDT are at higher risk of osteoporosis with splenectomy, iron overload, low fetal
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hemoglobin levels, and female gender [9,61,62]. Lower rates of osteoporosis are observed in patients
on iron chelation therapy or hydroxyurea therapy [9]. The most recent guidelines by the Thalassemia
International Federation (TIF) recommend that all patients ≥10 years of age be screened by yearly
assessment of lumbar spine, femoral neck, and distal ulna bone mineral density (BMD) via Dual
Energy X-ray absorptiometry (DEXA) [11]. Calcium and vitamin D supplementation is frequently
offered although its efficacy has not been fully established [63]. Bisphosphonates remain the gold
standard of thalassemia-associated osteoporosis treatment in both TDT and NTDT [63,64].
3.8. Endocrinopathies/Delayed Growth
It is important for the clinician to recognize endocrine disease as an important complication of
NTDT [65]. When compared to patients with TDT, the lower prevalence of endocrine disease may
be attributed to the lower extent, slower rate, and hepatic predominance of iron loading in patients
with NTDT [66]. Iron accumulation results in dysregulation of the hypothalamic-pituitary axis and
results in multiple endocrine disorders, including hypogonadism and delayed puberty. Splenectomy
is identified as a prominent risk factor for hypothyroidism [67].
The prevalence of endocrinopathies—such as hypogonadism, hypothyroidism,
hypoparathyroidism, diabetes mellitus, and adrenal insufficiency—in NTDT increases with
age [19]. Iron chelation therapy and hydroxyurea therapy have been associated with a lower frequency
of endocrine complications [9]. Fertility is not severely affected and patients can still achieve pregnancy
spontaneously; however, pregnancy in this patient population is complicated by high risk of abortion,
thromboembolic events, and intrauterine growth restriction in more than half of cases [68]. It is
recommended to run the following tests annually in all NTDT patients ≥10 years: calcium, phosphate,
25-hydroxyvitamin D, free thyroxine, thyroid stimulating hormone, fasting plasma glucose, and
adrenocorticotropic hormone stimulation test [65].
3.9. Renal Disease
Chronic anemia and hypoxia induce activation of fibroblasts and damage to tubular and
endothelial cells in the kidneys, resulting in interstitial fibrosis and proximal tubular cell
dysfunction [69]. Additionally, anemia is thought to decrease systemic vascular resistance and trigger
compensatory glomerular hyperfiltration. While this aims at maintaining homeostasis, it mediates
progressive renal damage and decline in glomerular filtration rate in the long run [70]. Iron overload
has also been suggested as a prominent player in tubular and glomerular dysfunction. End-stage
kidney disease is a possible end-result of anemia and iron overload-mediated kidney damage [71].
4. General Management
We base this section mostly on the TIF 2013 management guidelines, [11]. Otherwise, guidelines
for specific morbidities mainly follow the general practice in non-thalassemic populations, although
some studies are under way to better understand the actual effect of the application of general
guidelines in the NTDT population [72].
4.1. Transfusion Therapy
Although regular RBC transfusion therapy is not required in NTDT, it is occasionally needed
during times of increased physiological stress such as severe infection, pregnancy, surgery, and
precipitous hemoglobin drops [2]. Symptoms and complications, rather than absolute hemoglobin
level, remain the best determinant of the need for RBC transfusion therapy in NTDT [11]. Poor growth
development in pre-adolescence, as well as some morbidities previously described, may indicate
the need for regular RBC transfusion therapy. Some NTDT patients reach a point where regular
transfusions become essential to maintain hemoglobin levels appropriate to sustain activity, growth,
and development and to prevent further skeletal deformities [5].
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Although definitive evidence is lacking, frequent RBC transfusion therapy is linked to reduced
NTDT complications, including leg ulcers, thrombotic events, pulmonary hypertension, silent
brain infarcts, and extramedullary hematopoietic pseudotumors [9,31,43,58,73]. Besides preventing
hypoxia-related complications, RBC transfusion therapy is thought to improve coagulation defects
and decrease the need for splenectomy [74]. Alternatively, RBC transfusion therapy is associated with
worsening of iron overload and cardiac dysfunction [12]. There is a risk of alloimmunization with RBC
transfusion therapy, especially in minimally transfused, pregnant, or splenectomized NTDT patients,
but this risk can be mitigated through full phenotypic blood matching [5].
4.2. Splenectomy
Splenectomy was commonly pursued in NTDT to help maintain higher hemoglobin levels.
In the light of increased morbidity with splenectomy, clinical practice has gradually shifted to
restricting it to very specific indications such as poor growth and development, hypersplenism
with symptomatic leukopenia and or thrombocytopenia, or symptomatic massive splenomegaly.
Splenectomy is accompanied by an increased risk of severe infections, especially life-threatening
post-splenectomy sepsis. Patients who will be splenectomized must receive the pneumococcal 23-valent
polysaccharide vaccine, Haemophilus influenzae vaccine, and the meningococcal polysaccharide vaccine
at least 2 weeks before the procedure [11]. The spleen scavenges procoagulant RBCs and platelets;
therefore, splenectomy predisposes to hypercoagulability and accompanying concomitant increase in
the incidence of PHT, silent cerebral infarcts, venous thromboembolism, and leg ulcers [5].
4.3. Hydroxyurea Therapy
Hydroxyurea induces γ-globin chain production, which combines with the excessive α-chains to
produce HbF, thus alleviating the α/β globin chain imbalance and subsequently improving ineffective
erythropoiesis [61]. Data from observational studies including OPTIMAL CARE suggests that
hydroxyurea therapy is associated with lower rates of extramedullary hematopoiesis, osteoporosis,
leg ulcers, hypothyroidism, and PHT [9]. Direct prospective evidence is still lacking and the clinical
benefit of hydroxyurea therapy has not been systemically established [11]. Several non-randomized
and retrospective studies have evaluated HbF inducers in NTDT and considered it to be safe and
clinically effective. An increase in hemoglobin level by at least 1 g/dL at 6 months of therapy is
considered to be an adequate response. Patients should be evaluated periodically afterwards to
ensure benefit is maintained and to detect adverse effects including rashes, alopecia, gastrointestinal
disturbances, and myelotoxicity [61].
4.4. Iron Chelation
A cut-off LIC value of >5 mg/g dw has been shown to be associated with significantly
increased risk of several NTDT morbidities. Any increase above 5 mg/g dw by 1 mg/g dw is
independently associated with increased risk of PHT, hypothyroidism, hypogonadism, osteoporosis,
and thrombosis [62,75]. It is recommended to assess LIC using MRI T2*, R2, or R2* pulse sequences
annually, in addition to serum ferritin level assessment every 3 months [11]. An interesting relationship
between LIC and serum ferritin has been verified and used to guide iron chelation therapy in patients
10 years of age or older especially in areas where MRI is not available. An LIC of >5 mg/g dw correlated
well with a serum ferritin of >800 ng/mL, defined as the level at which iron chelation therapy should
be initiated in NTDT. An LIC of <3 gm/g dw correlated well with a serum ferritin of <300 ng/mL
defined as the level at which discontinuing iron chelation in NTDT would be safe [76]. The drugs
currently available for clinical use for iron chelation include oral deferiprone in solution or tablet form,
deferoxamine in subcutaneous or intravenous injection, and oral deferasirox in dispersible tablet (DT)
or film-coated tablet (FCT) form. While all three of these drugs have proven their effectiveness as
iron chelators in TDT patients, deferasirox remains the only drug that has received Food and Drug
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Administration (FDA) and European Medicines Agency (EMA) approval for use in NTDT patients,
mostly based on the results extracted and published from the THALASSA trial [77].
4.4.1. Deferasirox
Based on the results of a placebo-controlled trial, deferasirox is the only iron chelating agent
clinically proven to reduce iron loading in NTDT patients. Initiation of therapy with deferasirox is
recommended at an LIC of≥5 mg/g dw and at an initial dose of 10 mg/kg/day. Once LIC drops below
3 mg/g dw, treatment should be interrupted. LIC measurement is to be monitored every 6–12 months
and serum ferritin every 3 months [61,78].
The most common side effects of deferasirox therapy include gastrointestinal disturbances, rash,
increased hepatic transaminases, and elevated creatinine. Some of the rare adverse effects include
gastrointestinal hemorrhage and severe renal and hepatic impairment. Side effects are most commonly
encountered at higher doses of 25–35 mg/kg/day [79]. Patients on deferasirox therapy should
be followed monthly with serum creatinine and urine protein/creatinine ratio. Increase in serum
creatinine and proteinuria may necessitate dose reduction or treatment interruption. Monthly follow
up of hepatic transaminases is also recommended. Additionally, contraception is recommended while
on deferasirox. Yearly ophthalmic examination and audiometry testing are recommended after starting
therapy [77,79–81].
4.4.2. Deferiprone
Deferiprone has not been extensively studied as deferasirox in NTDT. It lacks support of
large randomized controlled trials; however, results from single-arm, open-label trials and a recent
randomized controlled showed significant decrease in serum ferritin and LIC. Adverse effects
include agranulocytosis, neutropenia, arthralgias, elevated hepatic enzymes, and gastrointestinal
disturbances [82–84].
4.4.3. Deferoxamine
Studies of deferoxamine in NTDT have shown an increase in urinary iron excretion and a decrease
in serum ferritin [85]. Robust evidence of the clinical efficacy of deferoxamine in NTDT is lacking.
Significant adverse effects associated with deferoxamine therapy include skeletal abnormalities, growth
retardation, ocular disturbances, local infusion site reactions, and auditory disturbances [86,87].
4.5. Hematopoietic Stem Cell Transplantation
Until now, hematopoietic stem cell transplantation (HSCT) to replace mutant cell lines remains
the only curative remedy for all thalassemic disorders, with chances as high as 80% in HLA-matched
sibling donor transplants [88]. Gene therapy with lentivirus-mediated gene transfer of healthy genes
to affected cell lines and gene editing are also being studied [89,90].
5. Future Interventions
In the past decade, several therapeutic options have emerged for patients with β-thalassemia.
These advances aim at improving iron dysregulation, globin-chain imbalance, and/or
ineffective erythropoiesis.
5.1. Improving Iron Dysregulation
Minihepcidins, long-acting hepcidin analogs, are currently being studied in clinical trials with
hypothesized outcomes including decreasing iron absorption levels from the gastrointestinal tract,
regulating iron handling by macrophages, increasing hemoglobin concentration, and reducing
spleen size [91]. An alternative method for hepcidin levels is currently being investigated using
anti-sense oligonucleotides and small interfering RNA to block the hepcidin-degrading effect of
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TMPRSS6, a transmembrane protease [90,92]. Genetic ablation of TMPRSS6 also improved ineffective
erythropoiesis and decreased splenomegaly in β-TI, without a concomitant decrease in erythropoietin
production [23]. Normalization of RBC survival is a significant component of the effects of TMPRSS6
inhibition on both hemoglobin and spleen size.
5.2. Correcting Globin-Chain Imbalance
Gene therapy is a promising treatment modality in the management of thalassemia. Some recent
studies have described the long-term correction of murine models of human β-thalassemia and sickle
cell anemia by lentivirus-mediated gene transfer [93,94]. The emergence of gene editing technology,
whether by direct correction of genetic mutations in the endogenous DNA of the cell or by disruption
of specific DNA sequences in the genome, offers a new approach for treating β-thalassemia. This is
facilitated by site specific double strand breaks which can be induced with zinc finger nucleases,
transcription activator-like effector nucleases, meganucleases, and, more recently, clustered regularly
interspaced short palindromic repeats (CRISPR)/Cas9 system [89]. Other alternatives that could allow
more efficient and immediate treatment of β-thalassemia with genome editing include the disruption
of factors that silence the γ-globin genes, such as BCL11A or γ-globin repressive elements within the
β-globin gene locus [95,96].
5.3. Improving Ineffective Erythropoiesis
Recent studies have elucidated the roles of Janus Kinase 2 (JAK2) and the transforming growth
factor (TGF)-β superfamily in the control of erythropoiesis. Binding of erythropoietin to its cell
membrane receptor activates the cytoplasmic JAK2, which in turn activates multiple signal transduction
pathways to increase proliferation, differentiation, and survival of erythroid progenitors. JAK2 is
the only intracellular signal transductor of erythropoietin and is, therefore, a potential target to
treat conditions caused by disordered and ineffective erythropoiesis [15]. JAK2 inhibitors, such as
ruxolitinib, have shown promise for amelioration of average hemoglobin concentration and potential
spleen size reduction in patients with TDT; the results of such trials in TDT may lay the basis for
studies in NTDT especially in patients with enlarged spleens [97].
Two activin receptor fusion proteins, sotatercept (ACE-011) and luspatercept (ACE-536), have
been developed for the treatment of conditions caused by ineffective erythropoiesis, including
β-thalassemia. These recombinant proteins bind to select TGF-β superfamily ligands that regulate
late-stage erythropoiesis [98]. Thus, the mechanisms of action of sotatercept and luspatercept are
distinct from erythropoiesis-stimulating agents and erythropoietin, which act on earlier stages of
erythropoiesis. Available data indicate that luspatercept was generally well tolerated and had
a favorable safety profile. It reduced transfusion requirements and liver iron concentration among
patients with TDT and increased hemoglobin levels, reduced liver iron concentration, and improved
quality of life among those with NTDT [99]. Current ongoing clinical trials are looking at the efficacy
and safety of luspatercept in TDT and NTDT patients.
6. Conclusions
NTDT has a unique morbidity profile that generally starts manifesting later in life, when compared
to TDT. The complications seen in NTDT tend to follow the natural progression of the disease since
regular RBC transfusion therapy is not indicated. In order to better understand each complication and
its appropriate management, it is important to find correlations with the pathophysiological hallmarks
of the disease. Furthermore, the dramatic improvement in therapeutic practices and the observed
survival benefit in NTDT over the past decades uncover newer challenges associated with more
complicated comorbidities from long standing anemia, tissue hypoxia, and possibly iron overload.
Timely medical intervention remains of critical importance to curtail the development of long-term
complications that may reach the point of irreversibility.
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